Skip to content
ClinCalc Pro
Menu
Inactivated polysaccharide typhoid vaccine Pregnancy: eMC §4.6: animal reproduction studies have not been conducted with TYPHIM Vi and data on the use of this vaccine in pregnant women are limited. Therefore administration of the vaccine during pregnancy is NOT recommended; TYPHIM Vi should be given to pregnant women only if clearly needed and following an assessment of the risks and benefits. Lactation: it is not known whether this vaccine is excreted in human milk, and caution must be exercised when TYPHIM Vi is administered to a nursing mother.

Typhoid vaccine (inactivated)

Brand names: Typhim Vi, Typherix

An inactivated vaccine (Vi capsular polysaccharide injection) used to provide active immunisation against Salmonella Typhi for travellers to endemic areas and certain occupational groups.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: A single dose of 0.5 millilitre
Route: The preferred route of administration for this vaccine is intramuscular, although it may be given subcutaneously. Do NOT administer by intravascular injection - ensure that the vaccine does not penetrate a blood vessel.
Frequency: A single dose, given at least 2 weeks prior to potential exposure to infection with Salmonella typhi. Revaccination: a single dose at 3-yearly intervals in subjects who remain at risk from typhoid fever.
eMC §4.2 (TYPHIM Vi Solution for Injection - the Vi capsular polysaccharide typhoid vaccine, which matches this inactivated-vaccine page). The 0.5 mL single dose applies to adults and children over 2 years of age. CHILDREN UNDER 2 YEARS: as with other polysaccharide vaccines, the antibody response may be inadequate in children under 2 years of age (the SPC gives no separate dose for this group). ELDERLY: as for adults and children over 2 years of age. §4.4: this vaccine protects against Salmonella typhi only and gives NO protection against Salmonella paratyphi A or B or against non-typhoidal Salmonellae. Before administration, the recipient or their guardian must be asked about personal history, current health status and any adverse event after previous immunisations; in subjects with a history of a serious or severe reaction within 48 hours of a previous injection of a vaccine containing similar components, the need for vaccination must be carefully considered following a risk-benefit assessment. Facilities for the management of anaphylaxis should always be available, and epinephrine injection (1:1000) must be immediately available. Syncope can occur following, or even before, vaccination, especially in adolescents, and may be accompanied by transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery - have procedures in place to avoid injury from faints. Administer with caution to subjects with thrombocytopenia or a bleeding disorder, since bleeding may occur after intramuscular administration. Vaccination may not result in protection in all recipients, and immunogenicity may be reduced by immunosuppressive treatment or immunodeficiency, in which case it is recommended to postpone vaccination until the end of the disease or treatment; nevertheless vaccination of subjects with chronic immunodeficiency such as HIV infection is recommended even if the antibody response might be limited. The product contains less than 1 mmol sodium (23 mg) per dose, i.e. is essentially sodium-free. Record the name and batch number of the administered product for traceability.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance, to any of the excipients, or to any residual substances that may be present as traces such as formaldehyde or casein (§4.3)
  • Vaccination must be postponed in case of febrile or acute disease (§4.3)

Side effects

  • Very common: injection site pain (75.6% in adults, 52.6% in children and adolescents); myalgia (very common in both adults and children/adolescents, 14.6% in children and adolescents)
  • Very common in children and adolescents 2-17 years, common in adults: headache (13.5% in children and adolescents); injection site erythema (14.4% in children and adolescents)
  • Very common in children and adolescents, common in adults: injection site swelling/oedema/induration (16.5% in children and adolescents)
  • Very common in adults, common in children and adolescents: malaise and fatigue/asthenia. Fever was common in children and adolescents. Injection site pruritus was uncommon in adults
  • Frequency not known (post-marketing surveillance): anaphylactic and anaphylactoid reactions including shock; serum sickness disease; vasovagal syncope in response to injection; asthma; nausea, vomiting, diarrhoea, abdominal pain; allergic type reactions such as pruritus, rash and urticaria; arthralgia. Most adverse reactions appeared within 3 days after vaccination and most resolved spontaneously within 1 to 3 days after onset

Interactions

  • Separate injection sites must be used in case of concomitant vaccine administration (§4.5)
  • TYPHIM Vi may be administered during the same vaccination session with other common vaccines: yellow fever, diphtheria, tetanus, poliomyelitis, rabies prepared on Vero cells, meningitis A+C, hepatitis A and hepatitis B (§4.5)
  • Immunosuppressive treatment or immunodeficiency may reduce the immunogenicity of the vaccine; it is recommended to postpone vaccination until the end of the disease or treatment (§4.4)

Clinical monograph

How it works

The purified Vi capsular polysaccharide antigen stimulates a T-cell-independent humoral antibody response against the typhoid bacterium, conferring partial protection.

Prescribing in practice

  • Protection is incomplete, so vaccinees must still be counselled on food, water and personal hygiene precautions; booster doses are needed for continued exposure.
  • Administer well in advance of travel to allow time for the immune response to develop.
  • It does not protect against paratyphoid fever or other gastrointestinal pathogens.

Monitoring

No routine laboratory monitoring is required; observe briefly after injection for immediate hypersensitivity reactions.

Counselling the patient

  • Keep maintaining strict food and water hygiene as the vaccine does not give complete protection.
  • A repeat dose is required before further travel if exposure continues.
  • Mild soreness at the injection site, headache or low-grade fever may occur.

Evidence & guidelines

Use is guided by UK national immunisation guidance (the Green Book) and current travel-health recommendations.

Reference: UKHSA Green Book Ch.33; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.